Renovaro Biosciences Inc

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Renovaro, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. The company was founded by Rene Sindlev and Serhat Gumrukcu on January 18, 2011 and is headquartered in Los Angeles, CA.

Message from Renovaro Biosciences CEO, The Hon. Mark Dybul, MD LOS ANGELES, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (Nasdaq: RENB) Dear Shareholders, I am writing to provide you with an update on our recent news of signing a definitive agreement to combine with GEDiCube (GEDiCube Press Release) (Renovaro Press Release) and to share our vision for the promising future of our newly combined company if you, as shareholders, approve the agreement.

AI Company GEDiCube and Renovaro Biosciences Sign Definitive Agreement to Combine

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Renovaro Biosciences Inc. (NASDAQ: RENB) and GEDi Cube Intl Ltd. is fair to Renovaro shareholders. Under the terms of the proposed transaction, all of GEDi Cube's outstanding equity interests will be exchanged for shares of Renovaro common stock. Halper Sadeh encourages Renovaro shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Z.

RENB Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Renovaro Biosciences Inc. Is Fair to Shareholders

The combined company aims to accelerate precision, personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better targeted treatments, and drug discovery

Renovaro Biosciences and AI Health Company GEDi Cube Sign Definitive Agreement to Combine

LOS ANGELES & AMSTERDAM--(BUSINESS WIRE)--GEDi Cube Intl Ltd. (GEDi Cube), an AI medical technology company, and Renovaro Biosciences Inc. (NASDAQ:RENB) (Renovaro), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy, have signed a definitive agreement to combine, in which GEDi Cube will become a wholly-owned subsidiary of Renovaro in a stock-for-stock acquisition (the “Transaction”). If completed, the Transaction will result in a combined company that will offer advance.

GEDi Cube and Renovaro Biosciences Sign Definitive Agreement to Combine

LOS ANGELES, Aug. 30, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: RENB). Renovaro BioSciences congratulates GEDiCube on their joint effort to work to accelerate early diagnosis of cancer in clinical trials.

Renovaro BioSciences Welcomes GEDiCube Announcement of New Joint Effort

LOS ANGELES, Aug. 21, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: RENB). Renovaro BioSciences congratulates GEDi Cube on its appointment of Dr. Lester Russell as Chief Medical Officer. For more information: (https://gedicube.com/news).

Renovaro BioSciences Congratulates GEDi Cube on Appointment of its Chief Medical Officer

Enochian Biosciences Inc

LOS ANGELES, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Renovaro BioSciences Inc. (NASDAQ:RENB) (formerly NASDAQ: ENOB), an advanced, pre-clinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, has executed a binding, exclusive letter of intent to merge a subsidiary with the cutting-edge health AI company GEDi Cube Intl Ltd. The combined company would aim to accelerate diagnosis, enhance treatment effectiveness, discover new therapies, and expand access to life-saving technologies for cancer and other diseases.

AI Company GEDi Cube and Renovaro Biosciences Announce a Binding, Exclusive Letter of Intent to Merge, Accelerating Fight Against Cancer

News for Renovaro Biosciences Inc Stock (RENB)